{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:52:13Z","timestamp":1791075133681,"version":"4.1.0"},"reference-count":11,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ero.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EULAR Rheumatology Open"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ero.2026.100245","type":"journal-article","created":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:00:24Z","timestamp":1791072024000},"page":"100245","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combined interleukin-1 blockade for central nervous system inflammation in children with severe cryopyrin-associated periodic syndromes"],"prefix":"10.1016","volume":"2","author":[{"given":"\u00d6zlem","family":"Satirer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Hospach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadiya","family":"Parczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne M.","family":"Benseler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmin B.","family":"Kuemmerle-Deschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ero.2026.100245_bib0001","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s10875-019-00638-z","article-title":"CAPS and NLRP3","volume":"39","author":"Booshehri","year":"2019","journal-title":"J Clin Immunol"},{"issue":"6","key":"10.1016\/j.ero.2026.100245_bib0002","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJMoa055137","article-title":"Neonatal-onset multisystem inflammatory disease responsive to interleukin-1\u03b2 inhibition","volume":"355","author":"Goldbach-Mansky","year":"2006","journal-title":"N Engl J Med."},{"issue":"23","key":"10.1016\/j.ero.2026.100245_bib0003","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa0810787","article-title":"Use of canakinumab in the cryopyrin-associated periodic syndrome","volume":"360","author":"Lachmann","year":"2009","journal-title":"N Engl J Med."},{"issue":"6","key":"10.1016\/j.ero.2026.100245_bib0004","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1002\/art.40055","article-title":"Cerebrospinal fluid cytokines correlate with aseptic meningitis and blood\u2013brain barrier function in neonatal-onset multisystem inflammatory disease","volume":"69","author":"Rodriguez-Smith","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.ero.2026.100245_bib0005","unstructured":"European Medicines Agency. Kineret (anakinra): summaries of product characteristics. Amsterdam: European Medicines Agency; [Updated 2025 Sep 26; cited 2026 Sep 22]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kineret-epar-product-information_en.pdf"},{"key":"10.1016\/j.ero.2026.100245_bib0006","unstructured":"European Medicines Agency. Ilaris (canakinumab): summaries of product characteristics. Amsterdam: European Medicines Agency; [Updated 2025 Sep 26; cited 2026 Sep 22]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ilaris-epar-product-information_en.pdf"},{"key":"10.1016\/j.ero.2026.100245_bib0007","series-title":"ARCALYST (rilonacept) prescribing information","year":"2026"},{"issue":"7","key":"10.1016\/j.ero.2026.100245_bib0008","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1002\/art.34409","article-title":"Sustained response and prevention of damage progression in patients with NOMID treated with anakinra","volume":"64","author":"Sibley","year":"2012","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.ero.2026.100245_bib0009","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/art.42664","article-title":"Anakinra-associated systemic amyloidosis","volume":"76","author":"Alehashemi","year":"2024","journal-title":"Arthritis Rheumatol."},{"issue":"9","key":"10.1016\/j.ero.2026.100245_bib0010","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1136\/annrheumdis-2013-204877","article-title":"A 24-month open-label study of canakinumab in neonatal-onset multisystem inflammatory disease","volume":"74","author":"Sibley","year":"2015","journal-title":"Ann Rheum Dis."},{"issue":"7","key":"10.1016\/j.ero.2026.100245_bib0011","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1136\/annrheumdis-2021-221801","volume":"81","author":"Romano","year":"2022","journal-title":"Ann Rheum Dis."}],"container-title":["EULAR Rheumatology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050708126001448?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050708126001448?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:00:25Z","timestamp":1791072025000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3050708126001448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S3050708126001448"],"URL":"https:\/\/doi.org\/10.1016\/j.ero.2026.100245","relation":{},"ISSN":["3050-7081"],"issn-type":[{"value":"3050-7081","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined interleukin-1 blockade for central nervous system inflammation in children with severe cryopyrin-associated periodic syndromes","name":"articletitle","label":"Article Title"},{"value":"EULAR Rheumatology Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ero.2026.100245","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}],"article-number":"100245"}}